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SUMMARY 
 
For many years there have been many excellent mouse models of benign intestinal 
adenoma though not of later stage invasive disease. In this study we have attempted to 
generate a number of murine models that closely recapitulate the human disease by 
manipulating mutations that occur during colorectal cancer (CRC) progression.  
The p53 tumour suppressor gene is commonly mutated in sporadic CRC, though loss alone 
does not drive intestinal tumorigenesis. When we targeted p53 deletion to the adult murine 
intestine in concert with a single mutation in the Adenomatous Polyposis Coli (Apc) 
tumour suppressor gene, this led to an acceleration of tumorigenesis and an increase in the 
number of invasive tumours and more rarely metastasis. These invasive tumours closely 
resemble human tumours and importantly had many features of Epithelial to Mesenchymal 
Transition (EMT). Tumours in this background still formed at relatively long latencies 
suggesting other genetic events were occurring to drive the progression in the absence of 
p53. 
Up to 50% of colon cancers have a mutation in KRAS. Targeting mutant KrasG12D to the 
intestinal epithelium promotes hyperplasia though not tumorigenesis. In combination with 
Apc mutation there is an acceleration of tumorigenesis and a greater propensity to develop 
colonic tumours. To test whether Kras mutation caused a more marked phenotype in the 
background of p53 deficiency we generated VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice. 
Remarkably these mice develop invasive and rarely metastatic tumours in as little as 50 
days. Moreover even small tumours (less than 1mm) could be invasive. 
We believe these mouse models of invasive and metastatic intestinal adenocarcinoma will 
be an excellent tool to study the invasive and metastatic process in vivo. Moreover they 
should allow us to test the efficacy of drugs aimed to inhibit the invasion process. 
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OBJECTIVES 
 
The main objective of this thesis was to develop and characterise new murine models of 
human colorectal cancer (CRC) that recapitulate the human disease in a more related 
fashion, in particular the spontaneous appearance of tumours and also the progression from 
benign adenoma to invasive carcinoma and eventually metastasis. In order to achieve this, 
we wanted to base our models on the three most common mutated genes in CRC: APC, 
p53 and KRAS.  
These murine models would help to better understand the biology of CRC, allowing us to 
improve the treatment and therapies of patients and hopefully contributing to the fight 
against cancer.  
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1.1 Colorectal cancer 
Cancer is the leading cause of death worldwide. Among the main common types of 
cancers, colorectal cancer (CRC) is the third most common  type in men and the second in 
women worldwide and the one with the fourth highest mortality rate. In the United 
Kingdom, there are 304,200 new cases of cancer diagnosed every year (data from 2008, 
Globocan), where CRC represents the forth most common type of cancer, and more 
frequent in women rather than men. Over the past years, the incidence of CRC cases has 
remained practically the same, however, there has been a slight decrease in mortality, 
likely due to the improvement in the early diagnosis and treatment. (Ferlay et al. Globocan, 
2008; IARC, 2010). 
The etiological factors that increase the risk and contribute to the development of this 
disease are very wide and complex. Many dietary factors have been attributed to increased 
risk of this disease, the main association seems to be the combination of a diet rich in 
unsaturated fats, high in red meat and low in fibre. Other potential risk factors are more 
related with lifestyle, such as poor physical activity and alcohol consumption. (Slattery et 
al. 2000). More firmly associated factors are medical conditions such as Crohn’s disease or 
Ulcerative Colitis and a wide spectrum of inherited and somatic conditions such as 
Familial Adenomatous Polyposis (FAP), Gardner syndrome or Turcot’s syndrome. Patients 
with these syndromes, which all have mutations in APC, have double the risk of having 
CRC in a first-degree relative (Johns et al. 2001; Fearon, E.R. 2011).  
The molecular genetics of CRC are being intensely investigated at the moment and there 
are many pathways found to be involved. Grossly, a rectal neoplasia integrates a 
combination of mutational activation of oncogenes and  inactivation of tumour-suppressor 
genes. Moreover, it seems to be the accumulation of these mutations rather than their 
chronologic order that determines the grade and characteristics of the tumour (Radtke et al. 
2005). The three main genes implicated in malignant transformation of CRC are APC, p53 
and KRAS, their different roles are described in more detail below.  
  
Chapter 1 INTRODUCTION 
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1.1.1 Role of APC in the Wnt signalling pathway 
APC exerts its main effect on CRC through the protein β-catenin, both of them have 
important roles in the canonical Wnt signalling pathway. This pathway has a main role in 
controlling cell fate, adhesion and cell polarity during embryonic development; and the 
majority of the CRC are initiated by mutations and deregulations in this pathway (Behrens, 
J. 2005).  
The Wnt pathway is first activated when a Wnt ligand binds to the seven trans-membrane 
receptors of the Frizzled family and low-density lipoprotein-receptor-related protein (LRP) 
co-receptors on the cell surface.  This binding activates Dishevelled (Dsh) which prevents 
the cytoplasmic degradation of β-catenin, through inactivation of  Glycogen Synthase 
Kinase3 (GSK3). β-catenin is then stabilized, accumulates in the cytoplasm, enters the 
nucleus and binds to the T-Cell Factor (TCF) to promote transcription of Wnt target genes 
(Radtke et al. 2005). 
APC forms part of the β-catenin destruction complex, together with the GSK3 and 
axin/conductin proteins. When this complex is active, β-catenin is phosphorylated by 
GSK3 and subsequently ubiquitinated and destructed by the proteasome pathway (Aberle 
et al. 1997). In the absence of β-catenin, the transcription of Wnt target genes is therefore 
suppressed. The loss of APC perturbs the Wnt signalling and allows the accumulation of β-
catenin within the cytoplasm and, therefore, the transcription of Wnt signalling target 
genes in a Wnt-independent way (Sansom et al. 2004). APC is mutated in the majority of 
human CRC (Powell et al. 1992; Miyoshi et al. 1992) and this mutation is generally seen 
as the gatekeeper in CRC, occurring early in the disease process (Vogelstein et al. 1988; 
Powell et al. 1992). 
1.1.2 The tumour suppressor gene p53 
P53, a protein encoded by the gene TP53, has been named as the “Guardian of the 
Genome” due to its broad role in regulating the cell cycle and conserving the stability of 
the genome by preventing mutations (Strachan et al. 1999).  
In a normal healthy cell, p53 is produced continuously and is normally associated to the 
oncoprotein Murine Double Minute (MDM2), a potent inhibitor of p53 that acts through 
the binding and degradation of the protein, shortening the half-life of p53 (Haupt et al. 
1997). However, when the cell is stressed by multiple assaults such as DNA damage, 
irradiation, shortened telomeres, hypoxia or oncogenic activation, p53 develops several 
14 
 
modifications that release it from MDM2 and this way becomes stable and activated. 
(Maltzman et al. 1984; Graeber et al. 1994; Junttila et al. 2010). 
The activation of p53 leads to its translocation to the nucleus resulting in the transcription 
of several target genes. This can result in three different actions in the cells through three 
different mechanisms: activation of temporary cell cycle arrest (quiescence), induction of 
permanent cell cycle arrest (senescence), or triggering of programmed cell death 
(apoptosis), (Shaw et al. 1992; Diller et al. 1990).  
Within the intestine, p53 induction has clear impact on intestinal cells e.g. induction of 
apoptosis (Fazeli et al. 1997). p53 is mutated in a large proportion (~50%) of human CRC  
(Baker et al. 1990); however, in contrast to APC, p53 mutations are not common in 
adenomas but more common in invasive carcinomas; this suggests that p53 mutation is a 
later event in tumour progression (Baker et al. 1990; Vogelstein et al. 1988). Moreover, 
mutations of p53 are usually point mutations occurring in the “hot spot” region of the 
protein and can exert an oncogenic effect beyond simple loss of the normal protein 
function (Brosh et al. 2009).  
1.1.3 KRAS and the Mitogen-Activated Protein Kinase (MAPK) 
Signalling 
MAPK signalling has an important role in the regulation of cell proliferation and 
differentiation. This cascade is dependent on multiple intermediates; the most important 
mediators are RAS and RAF proteins, the intracellular kinases Mitogen Extracellular 
Kinase (MEK) and Extracellular Signal-Related Kinase (ERK). RAS family consist of 
numerous proteins from which three of them (K-RAS, H-RAS and N-RAS) are often 
mutated in human cancers.  
RAS is normally associated with the inactive Guanosine Diphosphate (GDP) which is 
dissociated by the binding of the RTK-Grb2-Sos complex formed in the cell due to 
different external stimuli. When RAS is freed from its union with GDP, it has affinity to 
bind to Guanosine Triphosphate (GTP) and activates a downstream signalling cascade 
from the cell membrane to the nucleus through the activation of different kinases and 
proteins, the main intermediates of which are RAF, MEK and ERK. (Nandan et al. 2011). 
RAS oncogene was one of the first to be isolated from cancers and characterized 
(Malumbres et al. 2002). Its mutation causes RAS protein to be permanently bound to GTP 
and therefore leads to a hyper-activate state of the MAPK signalling pathway (Dhillon et 
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al. 2007). The KRAS oncogene is mutated in up to 50% of the colorectal tumours cases 
(Forrester et al. 1987; Bos et al. 1989) and KRAS mutations have also been detected in 
apparently normal mucosa in association with nearby carcinomas in some patients with 
CRC (Minamoto et al. 1995).  
1.1.4 Role of SRC family kinases in CRC 
Increase in SRC kinase activity has been demonstrated in colonic adenomas correlated 
with malignant potential and poor prognosis (Aligayer et al. 2002) and is, in fact, 
associated with induction of invasive phenotype in colonic tumour cells (Brunton et al. 
1997). This association is related to its anatomic and biochemical properties; on epithelial 
cells, SRC family kinases are located at adherent junctions (Calautti et al. 1998) and its 
activity targets numerous membrane proteins, several of them related to cellular growth, 
survival and adhesion (Leroy et al. 2009). One of these proteins is the complex formed by 
the association of E-cadherin with β-, α- and γ-catenins, which is essential for the 
establishment of cell adhesions (Calautti et al. 1998).  
SRC Family Kinases have multiple and different effects on cell adhesion, resulting in cell 
rounding and detachment (Fincham et al. 1998).  One of these important mechanisms is 
based on the catalytic activity of the SRC Family Kinases, which has been proven to be 
required for the disruption of cell to cell adhesion; while the exact mechanisms are still not 
clear, it is certain that the phosphorylation of β-catenin by SRC kinases decreases its 
affinity for E-Cadherin (Owens et al. 1999). This fact can be the key for the translocation 
of β-catenin to the nucleus and its consequent transcription and can be one of the reasons 
for the higher levels of β-catenin at the invasive edge of the tumours.  
 
1.2 Genetically Engineered Mouse (GEM) models of intestinal 
cancer 
There are many factors and pathways involved in the development of CRC. Extensive 
research has been done using cell lines derived from colorectal cancer, but there are several 
factors that can only been studied on live animals. In this aspect, mouse models have a 
special importance and uses due to the easy genetic manipulation and their biological 
characteristics of breeding, among others.  
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1.2.1 The Apc mice 
Several mouse models of CRC have already been developed; most of them in which the 
Apc protein is non-functional through the introduction of truncated mutations at different 
codons of the Apc gene. Main examples of these models are the formerly named Multiple 
Intestinal Neoplasia (MIN) mice  (now ApcMin/+), Apc∆716/+ or the Apc1638N/+ mice (Moser et 
al. 1990; Oshima et al. 1995; Fodde et al. 1994). The result of the Apc mutations in these 
mice is the development of numerous polyps, in both the small and large intestines. The 
condition resembles human inherited conditions such as the Familial Adenomatous 
Polyposis (FAP), in which the colonic polyps are usually of a serrated type (sessile 
adenomas) that, most frequently, do not progress towards a malignant counterpart and only 
a little percentage of them progress towards CRC. Intestinal adenocarcinomas were only 
found in the in the Apc1638N/+ model and very occasionally in the ApcMin/+ mice; these 
mouse models are, therefore, not adequate for the study of spontaneous and invasive CRC, 
which comprise 80% of the total cases in humans (Kinzler et al. 1996).  
Other problem of these models was that the homozygous condition was lethal (Moser et al. 
1995). The embryological lethality and the poor resemblance with the sporadic human 
CRC disesase was solved with the creation of the Apc580S mouse model (Shibata et al. 
1997). In this model, a pair of loxP sites are introduced in introns 13 and 14 of the Apc 
gene, the recombination by a Cre recombinase induces the deletion of the exon 14 leading 
to a framshift mutation at codon 580 that results in a non-functional protein. 80 % of the 
heterozygous Apc580S mice (named from now on as Apcfl mice) developed colorectal 
adenomas over 3 months after induction. The homozygous condition is not 
embryologically lethal and 83% of the mice developed colorectal adenomas 4 weeks after 
induction. This new mouse model allows better study of the spontaneously occurring CRC 
disease and, through the Cre-Lox technology, allowed the mutation to be targeted to 
specific regions within the intestinal tract (Marjou et al. 2004).  
1.2.2 Combination of Apc and p53 in a mouse model of CRC 
Due to their implication in colorectal  cancer development, the combination of these two 
specific mutations are the key to develop a murine model of human CRC and more 
specifically its progression to carcinoma and metastasis. 
Loss of p53 is achieved using the insertion of loxP sites in the introns 1 and 10 of the 
Trp53 gene, deletions of exons 2-10 with Cre recombinase results in a null allele (Jonkers 
et al, 2001). The mutant p53R172H, a point mutation commonly found in spontaneous 
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human tumours is created by using loxP flanked transcritional STOP cassette into intron 1 
of the p53 gene, the deletion of the STOP cassette using Cre recombinase results in the 
expression of the mutant R172H (Olive et al, 2004). 
Previous studies have found only little effect of p53 loss with  ApcMin or acute Apc loss at 
early intestinal tumorigenesis in vivo (Fazeli et al. 1997; Reed et al. 2008; Halberg et al. 
2000). P53 loss had no effect on crypt size, proliferation or apoptosis following Apc 
deletion, which reflects the fact that p53 expression is only increased in a small number of 
cells (Reed et al. 2008).  
1.2.3 Combination of Apc,  p53 and Kras in a mouse model of CRC 
Several studies have characterized the effect of mutant Kras in the colonic epithelium. 
While early studies with exogenous mutant showed Kras to induce growth arrest in 
primary cells unless accompanied by cooperating oncogenes or coincident loss of 
functional genes as p53 (Kamijo et al. 1997, Serrano et al. 1997), later studies with 
endogenous mutant in fact demonstrated its contribution to the development of CRC.  
Different types of mutations have been studied in order to determine the main mutation 
that is associated with human cancer. While KrasV12 activation does not alter intestinal 
homeostasis, it neither alters the architecture of the crypt-villus axis and has no or little 
additional changes after Apc loss in early stages of intestinal neoplasia but accelerates 
tumorigenesis and causes invasion in a later onset (Sansom et al. 2006).  
In contrast, activation of KrasG12D affects proliferation and differentiation of crypts, 
promoting hyperplasia in the colonic epithelium by increasing the number of proliferative 
progenitor cells in the tissue through activation of MEK and ERK pathways, although itself 
does not cause neoplasia (Haigis et al. 2008).   
When combined with a mutation in the Apc tumour suppressor gene, however, KrasG12D is 
able to promote tumour progression with a higher dysplastic grade than in those tumours 
formed with Apc loss alone (Haigis et al. 2008), accelerating the process of adenoma 
formation and reducing survival (Luo et al. 2011).  
Taking these studies into account, Kras mutation is regarded as an important key in the 
malignant transformation of colonic cancer cells and therefore its study and 
characterization is needed to be fully understood, even more following APC and p53 
mutations; in fact, combination of the three mutations APC, p53 and KRAS in cancer 
samples from human patients have been found  in 30-50 % of samples (Wang et al. 2007) 
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and the cooperation of KrasG12D and mutant p53 to initiate and develop oral tumour 
formation has also been shown (Acin et al. 2011). 
1.2.4 Other mouse models of CRC: Myc and Arf mice 
c-MYC is a downstream Wnt target that controls proliferation, differentiation and 
transformation in the adult intestine (Bettess et al. 2005). Several studies have determined 
that approximately 70% of the human colonic tumours have up-regulated c-myc expression 
(Augenlicht et al. 1997). Following the fact that wild-type APC has a repressor effect over 
MYC in physiologic circumstances (He et al. 1998), it was demonstrated that after Apc 
deletion, there is a dramatic increase in the levels of MYC in the intestinal epithelium and 
there is a marked proliferation of cells with elongation of crypts (Athineos et al. 2010). 
Furthermore, recent studies have demonstrated the importance of MYC in an Apc deficient 
background demonstrating that complete deletion of Myc totally rescues the Apc-driven 
phenotype and that even a partial deletion (Myc heterozygosity) is able to reduce the 
proliferation of crypts up to 50% (Sansom et al. 2007; Athineos et al, 2010) when APC is 
lost. 
p19ARF (p14ARF in humans) is a protein encoded by the CDKN2A/INK4A locus. This locus 
has two transcripts that produce two protiens, p16INK4a and the Alternative Reading Frame 
(ARF) (Quelle et al. 1995). The ARF protein is not detectable in normal cells, however, its 
levels increase after oncogenic or hyperproliferative signals leading to activation of p53 
through the nucleolar localization of MDM2 (Weber et al. 1999). The tumour suppressor 
role of ARF, independent of p16INK4a, was confirmed by Kamijo et al. in a murine model in 
which mice lacking p19ARF developed tumours early in life (Kamijo et al. 1997). However, 
recent lines of research suggest a role of ARF in tumour promotion, although the 
mechanisms are still not well characterized. Humbey et al. demonstrated, in a mouse 
model of B-cell lymphoma with a mutant or null p53, that silencing of ARF limited the 
progression of the tumour (Humbey et al. 2008). Humbey et al. associated this finding 
with the role of ARF in increasing autophagy, a process that is necessary for cell survival. 
On the other hand, a recent study showed that expression of ARF induces the formation of 
a Myc/Miz1 complex that leads to the repression of multiple genes involved in cell 
adhesion and induces apoptosis (Herkert et al. 2010). Moreover, in this study they 
demonstrated that when apoptosis was inhibited the loss of cell-cell adhesion persisted, 
giving to ARF a possible role in tumour progression through an invasive phenotype.  
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1.3 Treatment of Colorectal Cancer 
Treatment of metastatic CRC continues to have limited efficacy in patients, and a large 
number of drugs aimed to treat the disease have resulted in toxicity or harming of the 
patient. Due to the multifactorial aspect of cancer, a personalized therapy would be the 
most effective method to treat the disease.  Therefore, knowing the mutations and 
pathways involved can assist in the endeavour to the identify more effective therapy or 
even the correct combination of drugs.  
Numerous drugs have been developed and tested for specific targets in the process of CRC 
development and metastasis. Current approaches are very different, some of them are 
oriented towards targets to activate autoimmunity against colorectal tumoral cells (Chou et 
al. 2012), but the majority are focused on key proteins  involved in  cancer pathways, such 
as epidermal growth factor receptor (EGFR) inhibitors or SRC Family Kinases.  EGFR 
inhibitors such as Cetuximab and Panitumumab have been studied in cases of metastatic 
CRC (Ballestrero et al. 2012), however, these inhibitors are not effective when a Kras 
mutation is present (Karapetis et al. 2008, Hecht et al. 2009). 
 
1.4 Thesis aims 
Considering the background information displayed in the introduccion, this thesis presents 
the work performed in Colorectal cancer research focusing on the development of a murine 
model that allows the study of this human disease in order to prevent and reduce the 
incidence of invasive and malignant transformation. Therefore, the main objectives of this 
work have been as follow:  
• The development and phenotypic characterization of murine models with mutations in 
Apc, p53, Kras, Myc and Arf; as well as the study of the interactions between these 
mutations when present concurrently in the same animal model. 
• The characterization of the effects of SRC family kinases on the progression to an 
invasive phenotype of the colonic carcinoma and the preliminary study of potential 
inhibitors (Dasatinib) in order to develop treatment therapies. 
• The development of cell lines extracted directly from tumours formed in the intestine 
of these genetically engineered mice able to conserve the tumoral phenotype in order 
to allow further in vitro studies.  
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2.1 Genetically Engineered Mouse (GEM) models of 
colorectal carcinoma 
All experiments were performed in accordance with UK Home Office guidelines and local 
ethical approval. Mice were maintained under non-barrier conditions and fed a standard 
diet (Harlan) and water ad libitum.  
Mice were examined twice per week for signs of intestinal tumours, such as paling feet, 
hunching and weight loss. Upon developing any 2 of these signs the mice were euthanized 
and underwent a full necropsy. Tumour invasion was assessed by histology. 
2.1.1 AhCre+ cohorts 
For the creation of the AhCre+ cohorts, the following alleles were used: Apcfl (Shibata et 
al. 1997), p53fl (Jonkers et al. 2001) and p53R172H (Olive et al, 2004). Activation of the 
relevant allele was induced using the inducible AhCre recombinase in which the plasmid 
pAhcre is inserted in the pronuclei of C57Bl/6 zygotes of mice, Cre-mediated 
recombination is obtained in several epithelial tissues, mainly liver and small intestine. 
AhCre expression activates specific genes and it is induced using 3 intra-peritoneal 
injections of 80 mg/kg β-naphthoflavone (Sigma, Dorset, UK), separated by 8 hours at ~6 
weeks of age, as has been described previously (Ireland et al. 2004). C57Bl/6 mice were 
used for all the AhCre+ cohorts. 
The experimental cohorts were generated by crossing AhCre+ Apcfl/+ mice with either 
p53fl/+ or p53R172H/+ mice. The progeny were then interbred to yield the cohorts of AhCre+ 
Apcfl/+ p53+/+; AhCre+ Apcfl/+ p53fl/+; AhCre+ Apcfl/+ p53fl/fl; AhCre+ Apcfl/+ p53R172H/+ and 
AhCre+ Apcfl/+ p53R172H/fl. 
2.1.2 VillinCreER+ cohorts 
For the creation of VillinCre+ cohorts, the following alleles were used: Apcfl (Shibata et al. 
1997), p53fl (Jonkers et al. 2001), LSL-KrasG12D/+ (Tuveson et al, 2004), Mycfl (de Alboran 
et al, 2001), and p19ARF+/- (Kamijo et al, 1997). Activation of the relevant allele was 
Chapter 2 MATERIAL AND METHODS 
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induced using the inducible VillinCre recombinase, in which transgenes carrying the 
plasmid VillinCreER were injected into the pronuclei of oocytes from C57Bl/6 mice 
(Marjou et al, 2004). VillinCreER expression activates the specific gene and it is induced 
using a single intra-peritoneal injection of 80mg/kg of tamoxifen (Sigma) at ~60 days of 
age. C57Bl/6 mice were used for all the VillinCre+ cohorts.  
p53fl/+ mice were mated to VillinCreER+ Apcfl/+ mice. The progeny was then interbred to 
yield the cohorts of VillinCreER+ Apcfl/+ p53+/+; VillinCreER+ Apcfl/+ p53fl/+ and 
VillinCreER+ Apcfl/+ p53fl/fl.  
Conditional LSL-KrasG12D/+ mice were mated to VillinCreER+ Apcfl/+ p53fl/+ mice and the 
progeny from these crosses was interbred to obtain the cohorts VillinCreER+ Apcfl/+ p53fl/fl; 
VillinCreER+ Apcfl/+ KrasG12D/+ and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+. 
Myc colonies were created by mating Mycfl/+ mice with VillinCreER+ Apcfl/+ p53fl/fl and 
VillinCreER+ Apcfl/+ p53fl/fl LSL-KrasG12D/+ to obtain the following cohorts: VillinCreER+ 
Apcfl/+ p53fl/fl Myc+/+; VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+; VillinCreER+ Apcfl/+ p53fl/fl LSL-
KrasG12D/+ Myc+/+ and VillinCreER+ Apcfl/+ p53fl/fl LSL-KrasG12D/+ Mycfl/+. 
Arf colonies were created by mating p19ARF+/- mice with VillinCreER+ Apcfl/+ p53fl/fl LSL-
KrasG12D/+ to yield the following cohorts: VillinCreER+ Apcfl/+ p53fl/fl LSL-KrasG12D/+ Arf 
+/+;  VillinCreER+ Apcfl/+ p53fl/fl LSL-KrasG12D/+ Arf +/- and VillinCreER+ Apcfl/+ p53fl/fl LSL-
KrasG12D/+ Arf -/-. 
2.2 Genotyping of mice 
The genotyping of the mice was performed externally by Transnetyx (Cordava, TN). 
2.3 Dasatinib treatment 
For the Dasatinib experiment, mice from the VillinCreER+ Apcfl/+ p53fl/fl LSL-KrasG12D/+ 
colony were induced with a single intra-peritoneal injection of tamoxifen (8mg/kg) and 
were dosed daily 60 days after induction by oral gavage with 10mg/kg Dasatinib (Bristol-
Myers Squibb, Princeton, NJ) in 80mmol/L citrate buffer. Untreated controls were induced 
similarly with a single intra-peritoneal injection of tamoxifen (8mg/kg). A lower dose of 
tamoxifen (8mg/kg) was used in this dasatinib experiment to slow the development of 
tumours and therefore obtained better time frame to assess the treatment since the mice 
induced wih the 80mh/kg dose became ill too abruptly as to be able to treat them 
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effectively. The mice were monitored regularly and upon developing signs of intestinal 
tumours were euthanized and underwent a full necropsy.  
2.4 Tissue sampling 
For the tumorigenesis study, the entire intestine was removed and flushed with water. Both 
small intestine and colon were mounted ‘en face’ and fixed overnight in either methacarn 
(60% methanol, 30% chloroform and 10% glacial acetic acid) or 10% neutral buffered 
formalin. Lesions were then scored macroscopically and the small intestine and colon were 
then wound into a roll in 10% neutral buffered formalin.  
For the metastatic study, lungs, liver, spleen and lymph nodes were collected and fixed in 
10% neutral buffered formalin. All the samples, intestine and organs, were incubated 
overnight in formalin (long fixation) and subsequently embedded in paraffin, sectioned at 
5-10µm and stained with haematoxylin and eosin prior to microscopic analysis. 
2.5 Histology 
Samples were observed under a light microscope (Olympus BX51). Intestinal neoplasms 
were characterized and classified according to the human clasiffication of malignant 
tumours or TNM staging (Edge, S.B., et al. 2010) as follow: non-invasive when the 
neoplasia was restricted to the mucosa; superficially invasive (T1-T2) when the neoplasia 
invaded the submucosa and/or infiltrated superficially (less than half of its thickness) the 
muscularis propria; and deeply invasive (T3) when the neoplasia invaded the full thickness 
of the muscularis propria. Whenever tumours invaded through the surface of peritoneal 
organs this was classified as T4. Organs were checked and metastasis, if found, were 
characterized and classified as metastasis in either regional lymph nodes (N1) or in distant 
organs (M1).  
This classification of tumours in the mice, according with the human classification, was 
assessed and stablished by the student helped and advised by Dr. Ayala King, Research 
Fellow at the Beatson Institute for Cancer Research specialising in mouse pathology.  
2.6 Immunohistochemistry (IHC) 
2.6.1 p19ARF  
Sections were de-waxed by immersion in xylene and hydrated by serial immersion in 
100% ethanol (2 × 1min), 95% ethanol (2×1min), 70% ethanol (2×1min) and distilled 
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water (2×1min).  Antigen retrieval was performed by boiling the slides immersed in a pre-
heated Citrate buffer (Thermo scientific) diluted 1/10 with distilled water in a water bath 
for 20 minutes and then cooling in the solution for 30 minutes at room temperature (RT). 
Endogenous peroxidase activity was blocked by incubation in 3% hydrogen peroxide in 
de-ionized water; the slides were then blocked with 10% normal goat serum (NGS) for 30 
minutes at RT. Primary anti-p19ARF antibody (Abcam, ab80 rabbit polyclonal) was applied 
overnight at 4oC in a concentration of 1/300 in 10% NGS. Secondary anti-rabbit antibody 
(Vector ABC Kit) was applied the following day for 30 minutes at a concentration of 1/200 
in 10% NGS. After washing, signal amplification was performed using the ABC Complex 
(Vector ABC Kit), applied for 30 minutes. After washing positivity was visualised with 
DAB and slides were counterstained haematoxylin, prior to being dehydrated in increasing 
concentrations of ethanol and mounted.  
2.6.2 pSrcTyr416 
Sections were de-waxed as described above and antigen retrieval was performed with the 
same technique using Ethylenediaminetetraacetic acid (EDTA, Thermo scientific) in a 
solution of 1/10 in distilled water. Endogenous peroxidase activity was blocked as 
described above and slides were blocked for 30 minutes at RT with 5%  normal goat serum 
(NGS). Primary anti-pSrc Tyr416 antibody (Cell signalling, #2101 rabbit polyclonal) was 
applied overnight at 4oC in a concentration of 1/200 in 5% NGS. Secondary anti-rabbit 
antibody (Vector ABC Kit) was applied the following day for 30 minutes at  a 
concentration of 1/200 in 5% NGS. After secondary antibody wash, signal amplification, 
DAB positivity visualisation and mounting of the slides were performed as described 
previously.  
2.6.3 B-catenin 
Sections were de-waxed and rehydrated as described. Peroxidase block was carried out in a 
solution of 1.5% hydrogen peroxide for 45 minutes. Antigen retrieval was performed in 
pre-heated Tris EDTA in a boiling water bath for 50 minutes. Slides were then cooled for 1 
hour and blocked with 1% BSA for 30 minutes. Slides were incubated with primary mouse 
anti-β-catenin antibody (Transduction Laboratories, C19220, mouse monoclonal) in a 
concentration of 1/50 in 1% BSA for 2 hours at RT and then with HRP-labelled polymer 
(Mouse Envision+ system, Dako) for 1 hour at RT. After washing, positivity was 
visualised with DAB and slides mounted as described above. 
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2.7 Cell culture 
Cells were extracted from tumours and crypts following the method of primary cell culture 
described by Sato and Clevers in 2009 (Sato, T., et al. 2009). Cells from murine intestine 
were purified and cultured in a matrigel 3D culturing system to support its laminin-based 
growth. Culture media was made up of ADF with 0.25% BSA, 0.01 % L-Glutamine, 0.01 
% HEPES and 0.01 % PenStrep (Gibco®). Growth factors were added every other day and 
entire media was exchanged after 7 days or before if required. Crypts were passaged after 
7-10 days by mechanical disruption with a P200 pipette.  
Cells were fed every other day with two main growth factors for the intestine, Epidermal 
Growth Factor (EGF, Prepotech) and Noggin (Prepotech). The receptor for EGF (EGFR) is 
widely detected in colon cancer cells and its binding strongly stimulates proliferation of the 
epithelial cancer cells (Dignass et al. 2001). Noggin, an antagonist to bone morphogenic 
protein (BMP) singnaling, is associated with formation of numerous new crypts units, 
therefore expansion in the crypt number. Due to the Apc mutation of these cell lines, there 
was no need to use R-spondin 1, an APC agonist.  
2.7.1 Crypt culture 
Mice were culled 3 days after induction with tamoxifen and their small intestine was 
flushed with cold Phosphate Buffered Saline (PBS) and longitudinally opened. Villi were 
scraped off using a glass coverslip. The small intestine was cut in small pieces (5mm) and 
washed around 8 to 10 times with cold PBS and left for 30 minutes at 4° C in a solution 
with 25 ml of 2mM EDTA in PBS. Crypts were then washed 4 times with cold PBS and 
the supernatant from the 2nd-4th washes was collected. Crypt fractions were combined and 
washed with 50 ml of Advanced DMEM/F12 (ADF, GIBCO®) and centrifuged at 1200 
rpm during 5 minutes to be collected after that and passed through a 70 µm cell strainer. 
Crypts were then washed with ADF and centrifuged at 800 rpm for 3 minutes other 3 times 
to be collected and re-suspended in Growth Factor reduced Matrigel (BD Bioscience) in a 
24 well plate. 500 µl of culture media, 25ng of EGF (Prepotech) and 50ng of Noggin, an 
inhibitor of BMP signaling (Prepotech) were added to each well.  
2.7.2 Tumour culture 
Mice were culled by a Schedule 1 method upon developing signs of hunching and weight 
loss; the intestine was flushed with cold PBS and tumours were removed, cut in little 
pieces and washed 2-3 times in cold PBS to be incubated for 10 min in 5mM EDTA at RT 
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with vigorous shaking inbetween. After removing the EDTA with 2 additional washes with 
PBS, adenomas were incubated in 4.5ml 10x Trypsin 2.5% (Gibco®) with 100µl 10x 
DNase buffer and 100U DNase (Roche) for 30 minutes at 37°C.  Tumours were then 
further dissociated mechanically by pipetting with P1000 and 5ml pipettes and collected in 
50ml of ADF after being passed through a 70µm cell strainer. Cells were then centrifuged 
at 1200 rpm for 5 minutes and washed with ADF twice to plate in Matrigel as described 
above.  
The medium and growth factors used were the same as described for crypt culture. Passage 
was performed after 7-10 days with the same technique.  
Tumours collected for cell culture were only assessed grossly at necropsy, which impairs 
their classification as adenomas or adenocarcinomas if no obvious invasion was seen 
grossly.  
2.8 Subcutaneous tumour growth in mice 
Tumorigenic spheres maintained in culture were taken by mechanical disruption with P200 
pipette, washed with ADF and centrifuged at 800 rpm for 3 min. Cells were then re-
suspended in 150µl of matrigel and injected subcutaneously in the flank of 
immunodeficient CD1-nude mice. The number of spheres injected per mouse was ~50.  
Mice were monitored three times a week and tumours were measured from 6mm size. 
When the tumours became ulcerated or bigger than 15mm the mice were culled and the 
neoplastic mass was isolated and collected in 10 % neutral buffered formalin for histology 
processing as described. In order to check for possible metastasis, liver, spleen and lungs 
were also collected.  
To characterize the in-vitro growing of cells after the allografts, a small piece of the 
tumour was collected in cold PBS and cultured as described for adenoma culture.  
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3.1 The murine model of combined mutation of Apc and p53 
drives intestinal tumorigenenesis 
Previous studies failed to reveal the tumorigenic properties of p53 loss with deletion of Apc 
in vivo, in these studies p53 had no effect on crypt size, proliferation or apoptosis (Fazeli et 
al, 1997; Reed et al, 2008; Halberg et al, 2000). All these experiments were performed 
with rapid models of APC such as ApcMin,  we believe the use of Apcfl mouse model could 
overcome this given the longer latency of tumour development in these mice. Having this 
longer latency and the formation of occasional invasive carcinomas with this model, it is 
possible to more accurately model the human disease and better understand the 
transforming properties of p53 mutations in APC-mediated tumourigenesis. 
3.1.1 Loss of a single copy or both p53 alleles in an Apc deficient 
background accelerates tumorigenesis 
It has been previously shown that deletion of one copy of Apc in the adult intestine using 
the inducible AhCre recombinase results in mice developing tumours with long latencies, 
and which will convert into adenocarcinomas in approximately 25% of mice (Athineos et 
al. 2010).  
When a single p53 allele was lost or mutated (AhCre+ Apcfl/+ p53fl/+ and AhCre+Apcfl/+ 
p53R172H/+ cohorts) on this background, there was a significant acceleration in the 
tumorigenesis  compared to parental controls (AhCre+ Apcfl/+ p53+/+) (Log-Rank p=0.008). 
Deletion of the two copies of p53 (AhCre+ Apcfl/+ p53fl/fl) or mutation of one of the copies 
with deletion of the second one (AhCre+ Apcfl/+ p53R172H/fl) led to a remarkable acceleration 
in tumorigenesis comparing to either the control and heterozygous group (Log-Rank 
p<0.001). In fact, the median tumour onset was reduced to more than half in AhCre+ Apcfl/+ 
p53fl/fl and AhCre+ Apcfl/+ p53R172H/fl mice compared to controls (AhCre+ Apcfl/+ p53+/+). 
The survival was no different between the AhCre+ Apcfl/+ p53fl/+ and AhCre+ Apcfl/+ 
p53R172H/+ cohorts or between the AhCre+ Apcfl/+ p53fl/fl and AhCre+ Apcfl/+ p53R172H/fl 
cohorts. There was neither difference in tumour size or number among the different 
groups, indicating that all the mice were at a similar stage of tumour development when 
euthanized (Figure 1). 
Chapter 3 RESULTS 
27 
 
Figure 1: Apc driven tumourigenesis is accelerated by p53 deletion/mutation.  
a) Kaplan-Meier survival analysis. There was a significant difference in tumour-free survival 
between the AhCre+ Apcfl/+ p53+/+ cohort (n=15) and both AhCre+ Apcfl/+ p53fl/+ (n=20) and Apcfl/+ 
p53R172H/+ (n=14) cohorts (Log-Rank p=0.008). There was a further increased acceleration in 
tumorigenesis between AhCre+ Apcfl/+ p53fl/fl (n=15) and the AhCre+ Apcfl/+ p53R172H/fl (n=18) cohorts 
and the heterozygote or wild type p53 cohorts (Log-Rank p<0.001). Graph belonging to a PhD 
thesis presented to the University of Glasgow by Brendan Doyle, 2010. 
b) There was no difference in either tumour number or size across the 5 cohorts studied. First 
graphic shows the total tumour number per mouse in each of the cohorts, (* represents outlying 
values). Second graphic shows the tumour size per mm2 in each mouse of the colonies. Graph 
belonging to a PhD thesis presented to the University of Glasgow by Brendan Doyle, 2010. 
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3.1.2 Loss of p53 alone is not sufficient for intestinal tumour 
development 
To evaluate the effect of loss of p53 alone in tumorigenesis, AhCre+ Apcfl/+ p53fl/fl mice 
were induced in similar way to the other groups. These mice had longer survival time than 
AhCre+ Apcfl/+ p53fl/fl mice but none of them developed intestinal tumours. In contrast, the 
mice developed other type of tumours such as lymphomas, sarcomas or occasional 
mammary tumours, squamous cell carcinomas and one endometrial carcinoma. This is 
explainedby low level cre-mediated recombination from the AhCre transgene in these 
tissues. Nonetheless, these results demonstrate that p53 loss alone is not sufficient to 
initiate intestinal tumour development and that another event, such as Apc loss, is therefore 
required. 
3.1.3 Mutation of a single copy of p53 is sufficient for the progression to 
invasive carcinoma 
All tumours which developed in the intestines of mice were examined under the 
microscope for characterization. High grade dysplasia (HGD) and invasive carcinomas 
were found in all the groups but at very different stages.  
33% (5/15) of the AhCre+ Apcfl/+ p53+/+ mice were identified with HGD and 27% (4/15) 
with invasive carcinomas. The percentages were similar in the AhCre+ Apcfl/+ p53fl/+ 
cohort, in which there was 40% (8/20) of mice with HGD and 25% (5/20) with invasive 
carcinomas. In contrast, the percentages were increased in the other cohorts. The rates of 
HGD and invasive carcinomas identified in these cohorts were, respectively, 93% (13/14) 
and 86% (12/14) in the AhCre+ Apcfl/+ p53R172H/+ cohort, 87% (13/15) and 80% (12/15) in 
the AhCre+ Apcfl/+ p53fl/fl cohort and 100% (18/18) and 89% (16/18) in the AhCre+ Apcfl/+ 
p53fl/R172H cohort (Figure 2).  
When examining the invasive tumours microscopically, there were several differences in 
the degree of invasion in a similar way to those seen in the human disease. Some tumours 
showed superficial invasion, equivalent to T1-T2 human tumours. Others invaded all the 
way through the muscularis propria and peritoneum, equivalent to T3-T4 in human CRC. 
A single AhCre+ Apcfl/+ p53fl/fl mouse was found to harbour a metastasis in a pancreatic 
lymph node (N1). Apart from the metastasis in the AhCre+ Apcfl/+ p53fl/fl cohort, the rest of 
the tumours were similar in terms of depth and differentiation in the three cohorts AhCre+ 
Apcfl/+ p53R172H/+, AhCre+ Apcfl/+ p53fl/fl and AhCre+ Apcfl/+ p53R172H/fl (Figure 3).  
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Figure 2: p53 point mutation promotes high grade dysplasia and an invasive phenotype. 
a) Percentage of high grade dysplasia in the tumours. Percentages were higher in mice having 
either deletions or mutations affecting both copies of p53 (either AhCre+ Apcfl/+ p53fl/fl or AhCre+ 
Apcfl/+ p53R172H/fl) than in controls (AhCre+ Apcfl/+ p53+/+) or the heterozygous condition (AhCre+ 
Apcfl/+ p53fl/+). The single loss of p53 function (AhCre+ Apcfl/+ p53R172H/+) had as well very high 
degree of high grade dysplasia. Graph belonging to a PhD thesis presented to the University of 
Glasgow by Brendan Doyle, 2010. 
b) Percentage of mice with invasive carcinoma. There was a marked increase in the number of 
invasive carcinomas developed in mice with deletions or mutations of both copies of p53 (either 
AhCre+  Apcfl/+ p53fl/fl or AhCre+ Apcfl/+ p53R172H/fl) or a single loss of p53 function (AhCre+ Apcfl/+ 
p53R172H/+)than controls (AhCre+ Apcfl/+ p53+/+) or the heterozygous condition (AhCre+ Apcfl/+ p53fl/+). 
Graph belonging to a PhD thesis presented to the University of Glasgow by Brendan Doyle, 2010. 
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Figure 3: Variation in the invasion of the tumours. 
a) Superficial muscle invasion through the inner muscular layer (arrow). T2 stage. 
b) Full thickness invasion, extending to the serosa but without perforating it (arrow). T3 stage.  
c) Infiltration through the serosa and extension to the peritoneum with associated inflammatory 
reaction (arrow). T4 stage. 
d) Metastatic carcinoma in a pancreatic lymph node. N1 stage.  
Pictures belonging to a PhD thesis presented to the University of Glasgow by Brendan Doyle, 
2010. 
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3.1.4 Invasive edge of tumours exhibit EMT changes  
Having proven the histologic resemblance between tumours in these mouse models and 
human CRC, we decided to assess this resemblance at the molecular level. EMT is meant 
to be a critical step in the development of invasive carcinoma and progression to 
metastasis. E-cadherin loss and ZEB1 expression are two main markers of EMT 
(Schmalhofer et al. 2009). ZEB1 is a member of the Zinc finger homeobox family whose 
action represses E-cadherin from transcription and is upregulated at the invasive front of 
CRC (Spaderna et al. 2006).  
IHC for ZEB1 and E-cadherin was performed on several invasive tumours, the results 
correlated with the presumed theory. ZEB1 expression was elevated at the invasive front in 
a similar manner as E-cadherin expression was decreased (Figure 4a-b).  
Furthermore, E-cadherin loss is related with nuclear transcription of β-catenin through 
activation of WNT signalling pathway (Brabletz et al. 2001).  To confirm this upregulation 
of β-catenin at the invasive edge of the tumours, we performed the β-catenin IHC in a 
subset of invasive tumours. There was a clear positive nuclear staining in cells situated at 
the invasive edge, whilst the cells at the bulk of the tumour expressed both nuclear and 
cytoplasmic positive staining (Figure 4c).  
These data suggest that EMT actually takes place at the invasive front of these tumours, 
and that is correlated with β-catenin expression. The similarities between human CRC and 
these mouse models are therefore strongly supported. The expression of all of these 
markers was similar in the different cohorts AhCre+ Apcfl/+ p53R172H/+, AhCre+ Apcfl/+ 
p53fl/fl and AhCre+ Apcfl/+ p53R172H/fl.  
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Figure 4: EMT markers at the invasive edge of the tumours. 
a) IHC for ZEB1. Its expression is positively stronger (nuclear and cytoplasmic red staining) at the 
invasive edge of the tumour (^ and *) comparing to the central part of the tumour (#). Arrows depict 
nuclear staining at the invasive front: the expression of the dissociated cells (arrowheads) is 
stronger than the cells that still conserve epithelial properties (arrows) as show by red nuclear 
staining.  
b) IHC for E-cadherin. Its expression, predominantly cytoplasmic, is much stronger at the centre of 
the tumour (#) than at the invasive edge (*). 
c) IHC for β-catenin. Its expression is much stronger and predominantly nuclear at the invasive 
edge (arrow) than at the centre of the tumour, where it is more cytoplasmic.  
Pictures belonging to a PhD thesis presented to the University of Glasgow by Brendan Doyle, 
2010. 
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3.2 Modelling the invasive properties of colorectal cancer in an 
Apc p53 Kras mouse model 
Considering the interactions among these three main genes, APC p53 and KRAS, in human 
CRC, we decided to investigate the role of Kras mutation in our model to assess whether 
this can finally reveal the phenotype of p53 loss. Germline embryonic expression of an 
endogenous KrasG12D allele is lethal (Tuveson et al. 2004). Cre-recombinase models for 
endogenous Kras have been created and used for demonstrating its ability to develop 
hyperplasia and carcinomas in lung, pancreas, ovaries and myeloproliferative diseases. 
(Jackson et al. 2001; Hingorani et al. 2003; Chan et al. 2004; Johnson et al. 2001; Tuveson 
et al. 2004). Due to Cre leakiness we were unable to generate adult AhCre+ KrasG12D/+ 
mice so instead we crossed mice to a different intestinal inducible Cre recombinase, the 
VillinCreER, which induces recombination in both the small intestine and colon upon 
tamoxifen administration. 
3.2.1 Additional p53 deletion or Kras mutation reduces the survival of 
mice deficient for Apc loss  
To first confirm the impact of p53 deletion or Kras mutation on mice in which one copy of 
Apc was deleted in the adult murine intestine using the VillinCreER technology, we first 
created mouse colonies with these different genotypes: VillinCreER+ Apcfl/+ , VillinCreER+ 
Apcfl/+ KrasG12D/+  and VillinCreER+ Apcfl/+ p53fl/fl. 
Comparing to mice with only one Apc copy deletion (VillinCreER+ Apcfl/+) that usually 
were able to survive an average of 400 days, mice carrying an additional p53 deletion 
(VillinCreER+ Apcfl/+ p53fl/fl) had the survival rate significantly reduced to less than 200 
days and mice carrying an additional Kras mutation (VillinCreER+ Apcfl/+ KrasG12D/+ ) had 
the survival rate highly reduced to a mean of 100 days (Figure 5). In the case of the 
VillinCreER+ Apcfl/+ KrasG12D/+ there was an increased number of tumours formed in the 
large intestine, predominantly in the colon, which could have contribute to the reduce in 
the lifespan.  
To develop a murine model with alterations in these three main genes (Apc, p53, Kras), the 
mice were intercrossed to yield the VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ cohort. Mice from 
this colony had a drastic reduction in the survival rate, being an average of 50 days. The 
reduction in this survival rates compare with the other three cohorts was significantly 
different (Figure 5). 
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Figure 5: Survival time comparing p53 deletion or Kras activation with one copy of Apc 
deleted.  
Kaplan-Meier survival curves demonstrating the survival times of VillinCreER+ Apcfl/+ (black line), 
VillinCreER+ Apcfl/+ p53fl/fl (blue line), VillinCreER+ Apcfl/+ KrasG12D/+ (red line) and VillinCreER+ Apcfl/+ 
p53fl/fl KrasG12D/+ (green line). There was a significant difference in survival between VillinCreER+ 
Apcfl/+ (n=15) cohorts and VillinCreER+ Apcfl/+ p53fl/fl (n=16) cohorts (Log Rank p=0.002) and a further 
significant difference between VillinCreER+ Apcfl/+ p53fl/fl (n=16) cohorts and VillinCreER+ Apcfl/+ 
KrasG12D/+ (n=16) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (n=20) cohorts (Log Rank p<0.0001). 
Survival rate between the cohorts VillinCreER+ Apcfl/+ KrasG12D/+ (n=16) and VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ (n=20) was also significant (Log Rank p=0.0002). 
Median survival values for each cohort are: 428 days for VillinCreER+ Apcfl/+ (black line), 86 days for 
VillinCreER+ Apcfl/+ KrasG12D/+ (red line), 59 days for VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (green line) 
and 186 days for VillinCreER+ Apcfl/+ p53fl/fl (blue line).  
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3.2.2 Apc p53 Kras genotype drives early invasive tumour formation 
Mice that developed signs of intestinal tumours such as pale feet or pain were culled and 
examined. Mice that died due to other reasons rather than small intestinal tumours were not 
included in the study. The tumours developed in the intestine of these mice were classified 
in terms of number, size and aggressiveness. Total number and size was assessed 
macroscopically, regardless whether those tumours were invasive or not, which could only 
by assessed histologicaly.  
Tumours formed in the colon in the VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+ Apcfl/+ 
p53fl/fl KrasG12D/+ colonies were extremely occasional; on the oher hand, the VillinCreER+ 
Apcfl/+ KrasG12D/+ cohort developed higher number of tumours in the colon, for a still 
unknown reason. Considering this, only tumours within the small intestine are included in 
this section of total number.   
The total tumour number across the three colonies (VillinCreER+ Apcfl/+ p53fl/fl, VillinCreER+ 
Apcfl/+ KrasG12D/+ and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+) was not statistically different, 
except between the VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
cohorts (Figure 6a). In terms of tumour burden (tumour area/mouse) and average of tumour 
size, the VillinCreER+ Apcfl/+ p53fl/fl developed bigger tumours and had higher tumour 
burden compared with either of the other two cohorts VillinCreER+ Apcfl/+ KrasG12D/+ and 
VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+. Neither tumour burden or tumour size was different 
between the VillinCreER+ Apcfl/+ KrasG12D/+ and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice 
(Figure 6b-c).  
When the tumours were examined under the microscope and classified as invasive and 
non-invasive (adenomas versus adenocarcinomas), there was a significant difference 
between the percentage of invasive tumours per mouse in the VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ mice, with almost 24% of invasive tumours; and the VillinCreER+ Apcfl/+ p53fl/fl 
mice with less than 12% (Figure 6d).  Tumours formed in the VillinCreER+ Apcfl/+ 
KrasG12D/+ cohort were never invasive, therefore this colony is not included in the invasion 
graphic (Figure 6d).  
Histologically, tumours from the VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice were identified 
as invasive even with a total size of as little as 1 mm, which differs from the invasive 
tumours of the VillinCreER+ Apcfl/+ p53fl/fl colony which were much bigger in size. 
Metastasis in other organs was only found in one mouse of the VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ cohort (Figure 7).  
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Figure 6: Apc p53 Kras mutations drive early invasive tumour formation.  
a) There was no significant difference observed in the total tumour number across the VillinCreER+ 
Apcfl/+ p53fl/fl (n=9) and VillinCreER+ Apcfl/+ KrasG12D/+ (n=5) cohorts (Mann-Whitney test p=0.14) and 
between the VillinCreER+ Apcfl/+ KrasG12D/+ (n=5) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (n=15) 
cohorts (Mann-Whitney test p=0.50). There was significant difference between the VillinCreER+ 
Apcfl/+ p53fl/fl (n=9) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (n=15) cohorts (Mann-Whitney test 
p=0.0467). 
b) There was significant difference in the tumour burden (tumour area/mouse) between the 
VillinCreER+ Apcfl/+ p53fl/fl (n=9) and VillinCreER+ Apcfl/+ KrasG12D/+ (n=5) cohorts (Mann-Whitney test 
p=0.0112) and between the VillinCreER+ Apcfl/+ p53fl/fl (n=9) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
(n=15) cohorts (Mann-Whitney test p=0.0008). There was no significant difference between the 
VillinCreER+ Apcfl/+ KrasG12D/+ (n=5) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (n=15) cohorts (Mann-
Whitney test p=0.1842). 
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Figure 7: Intestinal adenocarcinoma and metastasis in a VilinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
mouse.  
a) Primary intestinal adenocarcinoma, note the invasion beyond the mucosa (arrowhead) and 
through muscularis propria (arrow); inset: higher magnification of the invasive edge. The intestinal 
adenocarcinomas formed in the VilinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ cohort were histologically similar 
to those few adenocarcinomas formed in the VilinCreER+ Apcfl/+ p53fl/fl but smaller in size.  
b)  Metastasis into a regional lymph node (N1).  
c) Example of a non-invasive tumour. Neoplastic cells are restricted to the mucosa.  
a
 
b
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3.2.3 Invasive edge of tumours showed EMT changes 
In the previous mouse model with the AhCre+ Apcfl/+ p53R172H/+,  AhCre+ Apcfl/+ p53fl/fl or 
AhCre+ Apcfl/+ p53R172H/fl cohorts, we demonstrated upregulation of EMT markers at the 
invasive edge of the tumours. To investigate whether this was still happening in the 
VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mouse model, we examined the expression of a 
number of genes involved in candidate pathways. 
Mutant Kras has been previously seen to enhance the canonical Wnt/β-catenin signalling 
pathway in a mutant Apc background (Janssen et al. 2006). As with the AhCre+ Apc p53 
mouse model, in this VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mouse model we saw increased 
β-catenin levels at the invasive fronts. Moreover there was increased levels of p-ERK at 
the invasive front (Figure 8), which correlates with earlier in-vitro studies where oncogenic 
Kras mutation uncoupled Rho activation from stress fiber formation via a mitogen-
activated protein/ERK pathway leading to poor adhesion of these cells and enhancing their 
motility (Pollock et al., 2005). 
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Figure 8: Immunohistochemical analysis of VilinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ tumours. 
a) β-catenin is activated at the invasive edge (*) showed by the stronger expression compared to 
the bulk of the tumour (#). 
b) p-Erk is activated at the invasive edge (*), showed by the stronger expression compared to the 
bulk of the tumour (#). 
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3.2.4 SRC family kinases are required for nuclear β-catenin at the 
invasive front 
To see whether Src expression was correlated with β-catenin expression in our 
VillinCreER+ mouse models, we first evaluated the expression of Src and its correlation 
with the high levels of β-catenin previously found. We found high expression of Src at the 
invasive edge  in both of the mouse models, VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+ 
Apcfl/+ p53fl/fl KrasG12D/+ mice (Figure 9). 
To confirm the association between expression of Src with low E-cadherin and 
translocation of β-catenin to the nucleus, we performed a short term experiment with a Src 
inhibitor, Dasatinib. VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice treated with Dasatinib had 
lower levels of p-Src, lower levels of nuclear β-catenin and higher levels of E-Cadherin at 
the invasive front in comparison with the vehicle-treated mice,  (Figure 10).  
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Figure 9: Immunohistochemical analysis of Src expression. 
a) Src expression is higher at the invasive edge in a VillinCreER+ Apcfl/+ p53fl/fl tumour. 
b) Src expression is higher at the invasive edge in a VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ tumour. 
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Figure 10: Immunohistochemical analysis of short term invasive tumours. 
Tumours from vehicle-treated mice (a) and Dasatinib-treated mice (b).There was reduction of β-
Catenin, phospho-Src and restoration of membranous E-Cadherin at the invasive edge after 
Dasatinib treatment. Images are representative of at least 3 individual tumours. 
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3.3 Dasatinib treatment 
Several Src inhibitors have been studied, such as Saracatinib, Bosutinib or Dasatinib. 
Dastinib has been tested in pre-clinical studies with good results in other types of cancer 
such as prostate, breast, gliomas or pancreas (Araujo et al. 2010, Morton et al. 2010). More 
specifically, in a study developed at our institution, Dasatinib showed to prevent migration 
and invasion (and therefore metastasis) in a mouse model of pancreatic cancer (Morton et 
al, 2010). Since in our VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
mouse models, we had demonstrated high levels of Src expression at the invasive edge of 
tumours and the ability of Dasatinib to reduce this Src expression at the invasive fronts; 
thus we decided to follow the line of experiments being developed at our institution with 
Dasatinib and see whether it was also applicable to our CRC model.  
Given the rapid onset of clinical signs in the VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice, it 
was not possible to properly test a long term treatment such as Dasatinib. Instead, the dosis 
of the single intra-peritoneal induction with Tamoxifen was reduced to 8mg/kg, which 
slowed down the onset of clinical signs to an average of 140 days instead of  50 days with 
the 80mg/kg induction. In this study, we treated with Dasatinib mice carrying Apc p53 
Kras mutations (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+) with a dose of 10 mg/kg daily from 
60 days post induction until the appearance of clinical signs associated with intestinal 
tumours. The study was focused on evaluating the effect of the drug on tumorigenesis, life 
span, invasiveness and metastasis.  
Dasatinib treatment did not increase survival; treated mice became ill at the same time 
(around 140 days) as the control cohort (Figure 11a). There was neither difference in the 
tumour number or the average of tumour size between controls and treated mice (Figure 
11b-c). However, there was a decrease in the number of invasive tumours formed per 
mouse, with only 7% of adenocarcinomas in the treated mice against the 44% found in the 
controls. Histologically, non-invasive intestinal tumours from treated mice tended to be 
bigger in extension, with a marked hyperplasia of the tunica muscularis, but the neoplastic 
cells were restricted to the epithelial cell layer without invading into deeper tissues 
(Figure12). 
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Figure 11: Tumorigenesis study of Dasatinib-treated VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice. 
a) Kaplan-Meier survival curves demonstrating the survival times of untreated mice (n=12, red line) 
and Dasatinib-treated mice (n=11, black line). There was no significant difference between the two 
survival curves (p= 0.224). 
b) The total tumour number developed in the small intestine of mice did not differed between the 
controls (n=22) and Dasatinib-treated mice (n=10). Mann-Whitney test p=0.0721. 
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Figure 12: Dasatinib treatment prevents invasion throught the submucosa. 
a) Picture showing a non-invasive tumour from the treated-mice. Neoplastic growth is large in 
extension but it is restricted to the mucosa. There is marked hyperplasia of the tunica muscularis.  
b) Picture showing an invasive tumour form the untreated-mice. Neoplastic cells have invade 
through the tunica muscularis and reached the serosa.  
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3.4 Growing of tumoral cells in vitro  
In order to test the tumorigenic capacity of the tumoral cells from the different genotypes 
and their ability to grow in vitro, we performed several cultures of cells coming from four 
different genotypes: VillinCreER+ Apcfl/fl p53fl/fl, VillinCreER+ Apcfl/fl p53fl/fl KrasG12D/+, 
VillinCreER+ Apcfl/fl p53R172H/fl, VillinCreER+ Apcfl/fl p53R172H/fl KrasG12D/+. 
All the cultured cells were able to form round spheres within 3 to 4 days. The appearance 
of the spheres was, as has been described, with a peripheral thick layer of cells and a lumen 
that becomes filled with dead cells and cellular debris. After the passage, at one week of 
growth, single isolated cells were able to reconstitute new spheres. In accordance with the 
literature (Sato et al, 2009), the spheres started to bud with the formation of new small 
crypts adhering to the main sphere, giving the appearance of numerous crypts surrounding 
a central lumen.  
This pattern of growth was similar in both cells extracted from tumours and from  normal 
crypts, with no apparent difference in proliferation, specific quantification ot the pattern 
and time of growth was not performed. Spheres were segregated and re-plated at least three 
to four times, as well as frozen and thawed without loosing the characteristics described. 
No clear difference was recognized in the morphology or pattern of growth between the 
different genotypes, the pictures shown are representative of the different cohorts in culture 
and are not comparable to each other due to lack of specific quantification (Figure 13).  
 Figure 13: Crypt and tumour
a) Culture from crypts. These pictures show the appearance of the spheres formed by the cells 
isolated from crypts. As soon as two days of culture, individualized cells were able to form medium 
size spheres and started to bud around one week of culture or after 
was very similar in the different genotypes. 
 
 
b) Culture from tumours
isolated from the intestine of the mice. In a similar manner as cells extracted from crypts, as soon 
as 2 days of culture, big spheres were already formed and were able to bud in a few days. There 
was no difference in the morphology of the spheres between the genotypes.
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3.5 Subcutaneous tumour growth in allografted recipients 
With the cell culture in vitro, we demonstrated the capacity of these VillinCreER+ Apcfl/fl 
p53fl/fl, VillinCreER+ Apcfl/fl p53fl/fl KrasG12D/+, VillinCreER+ Apcfl/fl p53R172H/fl and 
VillinCreER+ Apcfl/fl p53R172H/fl KrasG12D/+neoplastic cells to maintain their tumoral 
phenotype and grow in culture into spheres recapitulating the original tumour in a 
matrigel-based matrix. In order to test whether these cells were also able to grow in tissue, 
we designed a preliminary pilot experiment in vivo, we injected a suspension of single cells 
into the subcutaneous tissue of the flank of a total of 12 immunocompromised mice. Mice 
were monitored to evaluate the neoplastic growth in their flank and were culled when the 
nodule become either ulcerated or bigger than 15 mm. Mice were culled between 14 and 
71 days after injection, the time of growing for these nodular tumours was no comparable 
since many mice had to be culled due to ulceration of the area, therefore this data was not 
comparable.  
Mice were injected with cells from the following genotypes: VillinCreER+ Apcfl/fl p53fl/fl, 
VillinCreER+ Apcfl/fl p53fl/fl KrasG12D/+, VillinCreER+ Apcfl/fl p53R172H/+ KrasG12D/+, 
VillinCreER+ Apcfl/+ p53fl/fl, VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+, VillinCreER+ Apcfl/+ 
p53R172H/+, VillinCreER+ Apcfl/+ p53R172H/+ KrasG12D/+. All the mice developed subcutaneous 
growths in their flank. The gross appearance of all the nodules was very similar, consisting 
in a non-encapsulated, round, white firm mass not attached to the surrounding tissue except 
in a few cases where the skin became ulcerated and the mass was adhered to the dermis. 
None of the tumours showed any infiltrative behaviour into the abdominal cavity, however, 
a few tumours grossly infiltrated the dermis, which was confirmed microscopically. There 
was no significant difference in the growing pattern among any of the different genotypes 
(data not shown). 
Tumours were collected for histological evaluation. Samples from visceral organs, such as 
liver, lungs and kidneys, were collected as well to search for possible metastasis. The 
histological appearance of the subcutaneous tumoral nodules was characterized by 
irregularly shaped acinar structures lined by a single layer of cuboidal epithelial neoplastic 
cells; the tumoral cells were moderately dysplastic and mitotic figures were frequently 
present. Acini contained principally cellular debris within the lumen and were separated 
and divided by a moderately thick matrix of loose to mildly dense fibrovascular stroma. 
There were frequent areas of necrosis within the tumours. No metastatic foci were found in 
any of the organs examined (Figure 14).  
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Histology revealed that the cells were able to recapitulate the original tumour phenotype, 
with proliferating acini and a moderate desmoplastic reaction. In the majority of the 
samples, the appearance of the tumour was even more aggressive and dysplastic than their 
original counterparts extracted from the murine intestine. Some of the tumours revealed 
infiltration into the dermal tissues without reaching the epidermis. There was no difference 
in the appearance of the neoplasm or the infiltrative behaviour among the different 
genotypes. 
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Figure 14: Histology from harvested allografts. 
a) Allograft formed with VillinCreER+Apcfl/+ p53R172H/+ Kras+/+ genotype cells taken from an intestinal 
tumours. The majority of the tumours grew in a nodular pattern as shown in this picture.  
b) Higher magnification of (a). Neoplastic cells were arranged in irregular patterns within variably 
sized acini (arrows) with either empty or cellular debris-filled lumens (arrowhead). Surrounding the 
acini there is mesenchymal cell proliferation (*).   
c) Allograft formed with cells taken from crypts of a VillinCreER+ Apcfl/fl p53R172H/+ KrasG12D/+  mouse. 
An intact muscular layer from the skin (*) is present, neoplatic cells (arrows) are not infiltrating the 
muscle. 
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d) Allograft formed with cells taken from crypts of VillinCreER +Apcfl/fl p53R172H/+ KrasG12D/+ genotype. 
Note the pleomorphic acinar-like structures formed by the neoplastic cells, in this example many of 
them are filled with karyorrhetic debris (“dirty necrosis”) indicated by the arrows.  
e-f) Allografts formed with cells taken from crypts of VillinCreER+ Apcfl/fl p53fl/fl KrasG12D/+ genotype. 
These are two examples of dermal expansion without invasion into the epidermis (*). Arrows 
indicate the limit of the neoplastic growth. Arrowhead is indicating a debris-filled lumen.  
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3.6 Other murine models of intestinal cancer 
3.6.1 Myc deletion 
As Myc is one of the Wnt target genes that was overexpressed at the invasive edge of our 
first AhCre+ Apc p53 (AhCre+ Apcfl/+ p53+/+; AhCre+ Apcfl/+ p53fl/+; AhCre+ Apcfl/+ p53fl/fl; 
AhCre+ Apcfl/+ p53R172H/+ and AhCre+ Apcfl/+ p53R172H/fl) mouse model (data not shown), 
we wanted to test whether Myc deletion would have an effect on the formation of 
adenocarcinomas. We intercrossed our VillinCreER+ Apc p53 Kras cohort with mice 
carrying loxp-inducible knockout Myc alleles (Baena et al. 2005). This yielded the 
following genotypes for the study: VillinCreER+ Apcfl/+ p53fl/fl Myc+/+, VillinCreER+ Apcfl/+ 
p53fl/fl Mycfl/+, VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Myc+/+, VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ Mycfl/+. Mice were bred and induced with tamoxifen following the same 
protocol as perviously described.  
The survival rates of mice carrying the VillinCreER+ Apcfl/+ p53fl/fl Myc+/+ genotype and 
VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+ genotype were, in both cases, around 200 days, which 
was not significantly different. The difference was neither significant when comparing 
tumour number and tumour burden between both cohorts (Apc p53 and Apc p53 Myc). 
After microscopic examination, the percentage of invasive tumours in the VillinCreER+ 
Apcfl/+ p53fl/fl Myc+/+ cohort was approximately 18% while the percentage of invasive 
tumours in the VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+ was slighlty increased (to 21%) but not 
significantly different (Figure 15). 
In the Apc p53 Kras cohort, the survival rate of VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice 
was around 50 days while the surival rate of mice carrying additional Myc deletion 
(VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Mycfl/+) was around 60 days; these results were not 
significantly different. There was no difference when comparing tumour number and 
tumour burden between both cohorts (Apc p53 Kras and Apc p53 Kras Myc). After 
microscopic examination, the percentage of invasive tumours was 14% in the VillinCreER+ 
Apcfl/+ p53fl/fl KrasG12D/+ cohort while it increased to 21% in the VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ Mycfl/+ cohort; these percentages were not significantly different (Figure 16).  
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Figure 15: Myc heterozygosity does not decrease formation of invasive tumours in the 
VillinCreER+ Apc p53 mouse model.  
a) Kaplan-Meier survival curves demonstrating the survival times of VillinCreER+ Apcfl/+ p53fl/fl Myc+/+ 
(black line, n=20) and VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+ (red line, n=27) cohorts. There was no 
significant difference in survival between the two cohorts (Log Rank p=0.114). 
b) There was no significant difference observed between the total tumour number across the 
VillinCreER+ Apcfl/+ p53fl/fl Myc+/+ (n=9) and VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+ (n=19) cohorts (Mann-
Whitney Test p=0.0858). 
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Figure 16: Myc heterozygosity does not decrease formation of invasive tumours in the 
VillinCreER+ Apc p53 Kras mouse model. 
a) Kaplan-Meier survival curves demonstrating the survival times of VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ Myc+/+ (black line, n=20) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Mycfl/+ (red line, n=17) 
cohorts. There was no significant difference in survival between the two cohorts (Log Rank 
p=0.177). 
b) There was no significant difference observed between the total tumour number across the 
VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Myc+/+ (n=36) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Mycfl/+ (n=8) 
cohorts (Mann-Whitney Test p=0.144). 
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3.6.2 Arf deletion 
Our VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mouse model of colon cancer easily allows us to 
further characterize the mechanisms of Arf tumour suppression in the absence of the 
canonical Wnt signalling and loss of p53 in combination with a Kras mutation. Mice 
lacking p19ARF were intercrossed to VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ colonies to create 
the following cohorts: VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf +/+, VillinCreER+ Apcfl/+ 
p53fl/fl KrasG12D/+ Arf +/- and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/-. 
The survival rate of the control cohort (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+) was 
established around 75 days which was very similar to the 80 days of survival in mice 
carrying deletion of one copy of Arf (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf +/-). In the 
case of double deletion of Arf (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/-) the survival rate 
was reduced to 50 days, which was still not significantly different from the previous two 
cohorts, the heterozygous condition and the control (Figure 17a).  
When comparing the total tumour number there was no significant difference across the 
three cohorts. Neither was there a difference across the cohorts in the tumour burden of the 
mice (Figure 17b-c). 
When the tumours were examined under the microscope and classified regarding the 
invasiveness through the intestinal wall, there was a significant difference between the 
control mice VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+, in which 14% of the tumours arising 
from the intestine were invasive; and mice carrying one deletion  (VillinCreER+ Apcfl/+ 
p53fl/fl KrasG12D/+ Arf +/-) or double deletion of Arf (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
Arf -/-), in which the percentages of invasive tumours were approximately 3% and 5.5% 
respectively (Figure 17d).  
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Figure 17: Arf deletion reduces the incidence of invasive tumours 
a) Kaplan-Meier survival curves demonstrating the survival times. There was no significant 
difference in survival between the Arf wildtype condition VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+  (n=7) 
and either the heterozygous VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf +/-  (n=8; Log-Rank p=0.72) or 
the homozygous condition VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/- (n=10; Log-Rank p=0.093). 
b) There was no significant difference observed in the total tumour number across the cohorts 
VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ (n=14) and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf +/- (n=10) 
(Mann-Whitney Test p=0.960); VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ and VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+ Arf -/- (n=9) (Mann-Whitney Test p=0.669); VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf +/- and 
VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/- (Mann-Whitney Test p=0.459). 
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4.1 Intestinal role of p53 mutation with an Apc loss background 
Mutations in the p53 gene are well recognized and categorized as one of the most 
important events in the development of intestinal cancer. However, its specific effects on 
the intestine and its relation with other mutated genes in this disease are still unknown. 
APC mutations occur early in the CRC process (Vogelstein et al. 1988), however, p53 
mutations are considered to occur more frequently in intestinal carcinomas and only rarely 
in adenomas (Baker et al. 1990). This way, p53 loss or mutation could give advantage in 
tumour progression after an APC mutation has already occurred in the intestine. In 
previous studies, p53 loss failed to demonstrate any effect on intestinal tumorigenesis 
(Fazeli et al. 1997). The work of Fazeli and colleagues assessed a model of early stage 
disease (ApcMin) in which mice become ill within a period between 80 to 210 days of age 
and only adenoma formation occurred in the intestine. As determined by the study of 
Baker et al,  p53 mutations occur more frequently in intestinal carcinomas than in 
intestinal adenomas, which suggests p53 mutation is a late event that occurs near the stage 
in which an intestinal adenoma develops into its malignant counterpart. Following this 
idea, we developed a longer-latency mouse model (AhCre+ Apcfl/+) in which the survival 
rate of mice was between 300 and 500 days. With this longer latency, an additional p53 
mutation or loss could be of selective advantage in the formation of intestinal 
adenocarcinomas and will confirm the role of mutations in the p53 gene in intestinal 
cancer.  
In this AhCre+Apcfl/+ mouse model, we obtained a significant acceleration in tumorigenesis 
with a single allelic p53 mutation or allele loss (AhCre+ Apcfl/+ p53fl/+, AhCre+ Apcfl/+ 
p53R172H/+) and the acceleration in tumorigenesis was even more pronounced when a 
mutant p53 occurred in a p53 loss background (AhCre+Apcfl/+ p53fl/fl, AhCre+Apcfl/+ 
p53R172H/fl) compared to controls (AhCre+Apcfl/+ p53+/+). These results confirm that loss of 
p53 and the R172H mutant have a role in the carcinogenic process in intestinal cancer. 
There was no difference in tumour number or size across the cohorts, which indicates all 
the animals were euthanized at the same stage of tumour development.  
Chapter 4 DISCUSSION 
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In order to confirm that the acceleration of tumorigenesis were not due to Apc or p53 
mutations alone and that, instead, it was due to the combined effect of both Apc and p53 
mutations, we bred mice with double deletion of p53 in an Apc wild type background 
(AhCre+ Apc+/+ p53fl/fl). None of these mice developed intestinal tumours; these mice 
became ill due to the occurrence of other non-intestinal tumours, such as lymphoma. With 
this experiment, we further clarified the collaboration between the deficiency or mutations 
in these two genes (Apc and p53) and we established p53 mutations as an important event 
in the development of tumorigenesis but not in the intestinal tumour initiation.   
The invasion of the tumours seen in the intestine differed between the different cohorts. 
Only a low percentage of invasive tumours were observed where p53 is wild type (AhCre+ 
Apcfl/+ p53+/+) while there was high percentage of invasiveness in either the cohorts with 
single p53 mutation (AhCre+Apcfl/+ p53R172H/+) and the homozygous condition (AhCre+ 
Apcfl/+ p53fl/fl) or with a mutation on a p53-deletion background (AhCre+ Apcfl/+ p53R172H/fl). 
There was, however, a similar percentage of invasive tumours in mice with single p53 loss 
(AhCre+Apcfl/+ p53fl/+) compare to controls (AhCre+Apcfl/+ p53+/+). These results 
demonstrate the enhanced oncogenic properties of the mutated p53 protein above single 
loss of the allele and the similar properties of double deletion and mutation with a 
concomitant Apc deletion. These analyses further confirm previous theories in that p53 
mutations occur late in the development of the disease and at the transition from adenoma 
to adenocarcinoma formation (Baker et al, 1990; Vogelstein et al, 1988). 
Our AhCre+ Apc p53 mouse model recapitulate several aspects of the human disease. 
Histological grading of invasive tumours from mice resulted in different grades from 
superficial to deep invasion and metastasis as it is also seen in the human disease following 
the TNM staging (Edge et al, 2010). Even more, when we analyzed the tumours looking 
for EMT markers, there was no significant difference between the AhCre+ cohorts Apcfl/+ 
p53fl/+, Apcfl/+ p53R172H/+, Apcfl/+ p53fl/fl and Apcfl/+ p53R172H/fl. E-cadherin and ZEB1 
expression, both markers of EMT changes (Schmalhofer et al, 2009), were 
immunohistochemiscally tested on invasive tumours. There was a decrease of E-cadherin 
and an increase of ZEB1 at the invasive front of the tumours and this was correlated with 
the nuclear translocation of β-catenin at the invasive front, manifested as increased 
intranuclear immunolabelling of this protein. This further characterized the model as an 
experimental model very similar to the human disesase, even at the molecular level. 
Metastasis is the cause of death in at least 50% of cases of CRC and often occurs long 
before cancer is diagnosed (Hölzel et al. 2009).  In the AhCre+ Apc p53 mouse model, only 
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one mouse developed metastasis to distant organs despite the aggressive appearance of the 
tumours examined on histological sections and the confirmed mesenchymal transition of 
cells at the invasive edges of tumours. Metastasis could have occurred in some other mice 
but not have been detected by the microscopic examination; this raises the question of 
whether histology of organs is a good method of detecting distant metastasis since only one 
microscopic section of the organ is examined. On the other hand, such a wide variety of 
factors are involved in the process of migration of cells through capillaries and 
stablishment of neoplastic cells in distant organs that it is probable that more events are 
involved in the process of metastasis and further studies are needed in order to develop a 
good metastatic mouse model of CRC.   
 
4.2 Establishing an in vivo model for intestinal cancer with Kras 
mutation and Apc p53 deletions.  
As previously discussed,  RAS is one of the main genes mutated in human CRC with a 
frequency of up to 50% of the cases (Forrester et al. 1987, Bos et al. 1989) and between 30 
and 50% in combination with APC and p53 deletions (Wang et al. 2007). Previous studies 
have suggested that mutant KrasG12D accelerates the progression to malignancy of colonic 
tumours in an Apc loss background (Haigis et al. 2008). Regarding these previous studies 
and considering a p53 mutation as unlikely to be selected for by Apc loss alone, we 
considered Kras mutation as the most likely event that will contribute to reveal the 
phenotype of p53 loss in an Apc loss background.  
It was not possible to continue the work on the AhCre model since the KrasG12D mutation 
is lethal in mice during fetal development because of leaky expression from the AhCre 
transgene. Instead of using AhCre , we reproduced the Apc p53 model with the VillinCreER 
transgene, which induces recombination in both the small intestine and colon in the adult 
mice upon tamoxifen induction.  In order to combine Apc and p53 loss with a Kras 
mutation, a lox stop lox KrasG12D/+ allele was crossed to mice carrying Apcfl and p53fl 
alleles creating the following colonies: VillinCreER+ Apcfl/+ , VillinCreER+ Apcfl/+ KrasG12D/+ 
, VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+. Survival rate and 
tumour number (when comparable) were slightly different between the AhCre+ Apcfl/+ 
p53fl/fl and the VillinCreER+ Apcfl/+ p53fl/fl as it has been exposed in the results. Given this 
finding, we decided not to compare both cohorts and, instead, create and characterized the 
whole VillinCreER+ model in order to have as much accurated results as we could.  
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We first confirmed the effect of p53 deletion or Kras activation alone on mice where one 
copy of Apc was deleted in the adult murine intestine using the VillinCreER technology. As 
expected, p53 deletion accelerated tumorigenesis in an Apc deficient background reducing 
the survival curve to less than 200 days; both adenomas and adenocarciomas were formed 
in the intestine of these mice. These results confirmed the effect of p53 loss on 
tumorigenesis when combined with Apc loss as we had previously showed in the AhCre+ 
Apc p53 model.  
Kras activation (VillinCreER+ Apcfl/+ KrasG12D/+) drastically accelerated the tumorigenesis, 
reducing the survival curve to 100 days, demonstrating the effect of Kras activation in 
intestinal tumorigenesis when combined with Apc loss and also suggests Kras activation to 
have more effect in the intestinal tumorigenesis than p53 deletion alone in an Apc loss 
background. In this VillinCreER+ Apcfl/+ KrasG12D/+ model, all the tumours formed in the 
intestine were numerous adenomas but no adenocarcinoma was found in any of the mice, 
howevere, there were numerous tumours formed in the colonic epithelium, alhtough any of 
them were adenocarcinoma.  The large total number of tumours, eventhough they were not 
invasive, is probably the explanation for the reduced survival curve of this VillinCreER+ 
Apcfl/+ KrasG12D/+ cohort; and the fact that tumours in the small intestine (only tissue 
considered for the graphics) were lower in number than those in the large intestine, 
explains the low tumour burden for this VillinCreER+ Apcfl/+ KrasG12D/+ cohort. With these 
results we confirmed Kras activation has an effect in the tumour progression, but it is not 
able by its own to induce malignant transformation.  
When combining deletions and  mutations of the three genes (VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+) there was a dramatic acceleration in the tumorigenesis with the survival time 
being reduced to as little as 50 days. These results highly differ from the controls 
(VillinCreER+ Apcfl/+) and even more with the VillinCreER+ Apcfl/+ KrasG12D/+ and 
VillinCreER+ Apcfl/+ p53fl/fl models which shows that deletions on these three genes have a 
combined effect during intestinal tumorigenesis and that Kras activation has a clear effect 
in revealing the mutated p53 phenotype in an Apc deficient background. 
With the VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ model, both adenomas and 
adenocarcinomas were found in the intestine of mice, but the size and conversion to 
adenocarcinoma had become uncoupled as some invasive tumours were less than 1 mm, 
when all invasive tumours in our previous mouse models (AhCre+ Apc p53 and 
VillinCreER+ Apc p53) had been much larger, this is reflected in the tumour burden graphic. 
These small tumours were able to invade through the full thickness of the intestinal wall 
66 
 
and there were even a few metastasis found in distant organs.  In fact, the percentage of 
invasive tumours found in VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mice was much higher 
(almost 70%) than the percentage of the VillinCreER+ Apcfl/+ p53fl/fl mice (less than 10%), 
which is reflected in the survival curves. These findings suggest the combined loss of Apc 
and p53 with Kras activation confers the neoplastic cells with increased ability to divide 
and invade adjacent tissues than with deletions of p53 or Kras activation alone when in an 
Apc loss background.  
In the previous AhCre+ Apcfl/+ p53fl/fl model we had proven the similarity between the 
mouse model and the human disease even at the molecular level through the EMT markers. 
Immunohistochemical analysis performed on the VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ 
model showed higher expression of β-catenin at the invasive front; furthermore, there were 
also increased levels of p-ERK at the invasive front. This is in concordance with previous 
studies of Apc Kras mouse models (Janssen et al. 2006) and clarifies the process that leads 
to a more aggressive behaviour of these tumours and their invasive characteristics. Our 
results show that intestinal adenocarcinomas achieve invasive capacity through the 
transition towards a mesenchymal phenotype, in which the combination of these three 
genes, Apc, p53 and Kras is involved. Furthermore this data suggests that the presence of a 
Kras mutation causes a strong selection for a p53 mutation, both in terms of tumour growth 
and progression; which is in contrast to Apc mutation alone, where there is little immediate 
selective benefit to losing p53.  
 
4.3 SRC family kinases and the conversion to malignant 
intestinal adenocarcinoma 
 
In the past, CRC has been associated with clear invasive fronts that have an upregulation of 
nuclear β-catenin and EMT markers and, recently, the expression of EMT markers in 
cancer stem cells has been associated with high levels of Wnt signaling genes. But for 
many years, these findings were not consistent with all the cells at the invasive front and 
no clear effector key for the activation of Wnt signalling pathway has been detected.  
One hypothesis concerns the correlation between the high levels of β-catenin at the 
invasive front with SRC expression, which is overexpressed in many invasive phenotypes 
(Brunton et al. 1997). SRC family kinases activity is involved in the detachment of cells by 
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disruption of cell-cell adhesions (Calautti et al, 1998; Owens et al, 2000) and, giving our 
results, this is possible to occur through the phosphorylation and destabilization of E-
Cadherin at adherens junctions. E-Cadherin is a cell-to-cell adhesion molecule to which β-
catenin is also attached. A destabilization of E-Cadherin by the explained mechanisms 
would therefore release β-catenin with its consequent translocation to the nucleus for 
transcription. This release would explain the higher expression of β-catenin found in cells 
localised at the invasive front, as these cells are undergoing a higher rate of division and 
mesenchymal transition. On the other hand, SRC family kinase are directly involved in the 
stabilization of cell adhesion through the tyrosin phosphorilation of β-catenin and recent 
studies have demonstrated a direct inhibition of this phosphorilation and therefore decrease 
in the growth and motility of colorectal cancer cells by using the Src inhibitor Bosutinib 
(Calautti et al, 1998; Coliccia et al, 2006; Müller et al, 1999).  
To prove the relation between SRC expression with β-catenin and E-cadherin expressions 
at the invasive front, we designed an short-term experiment using one of the inhibitors of 
Src family kinases: Dasatinib. As expected, tumours from treated mice had lower 
expression of β-catenin and higher expression of E-cadherin at the invasive front compare 
with the untreated controls; in addition to lower levels of Src expression. With this 
experiment we further proved the direct relationalship between activity of SRC family 
kinases and E-cadherin at adherent junctions and its effects above β-catenin. We could 
state, therefore, that SRC family kinases are required for the deregulation of Wnt signaling 
at invasive fronts.  
Following this line, given that in this short-term experiment Dasatinib was able to reverse 
the EMT phenotype through restoration of E-Cadherin levels at the invasive front, we 
designed a long-term experiment to assess the capacity of Dasatinib to suppress invasive 
adenocarcinoma formation. Dasatinib clearly reduced the number of invasive 
adenocarcinoma in treated mice compare with untreated controls, despite not having any 
effect in reducing the survival time. Dasatinib did not prevent adenoma formation and mice 
came down due to the burden of numerous intestinal adenomas. In spite of this, Dasatinib 
should be considered as part of the treatment in patients with high risk of stage II CRC.   
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4.4 Single cells from harvested tumours were able to reproduce 
the neoplastic phenotype 
We have successfully created a murine model of invasive intestinal cancer, driving some of 
the pathways and proteins implicated in the process. However, there is still much to know 
about the molecular keys that can take place in the overall process of intestinal 
tumorigenesis. There has recently been much interest in the overlap of normal intestinal 
stem cell (ISC) markers with colorectal cancer stem cell markers. Two recent studies have 
worked on the prediction of a good or poor prognosis of human CRC based on these ISC 
markers (Merlos-Suarez et al. 2011; de Sousa et al. 2011). While one of the studies confers 
poor prognosis to the high expression of the ISC marker genes, the other attributes the poor 
prognosis to the methylation of this subset of genes. In any case, both studies agreed in that 
a Wnt high population marks a colon cancer stem cell population.  
In our studies, we have seen high levels of Wnt signaling downstream genes in association 
with the invasive front of tumours and expression of a number of ISC and EMT markers. 
Working with isolated tumoral cells would allow further characterization of these protein 
properties in the CRC. A common difficulty that the studies of Merlos-Suarez and de 
Sousa could have found is that their experiments were developed from sorted populations 
of cancer cells and thus the precise expression of these signatures in a cell by cell basis in 
the tumour is unclear. The design of an experiment using tumoral cells harvested from 
neoplastic murine intestine to re-grow them in culture plates would hopefully offer the 
ideal scenario for this study.  
We succesfully cultured cells extracted from the intestines of the VillinCreER+ Apc p53 and 
VillinCreER+ Apc p53 Kras mice (VillinCreER+ Apcfl/fl p53fl/fl, VillinCreER+ Apcfl/fl p53fl/fl 
KrasG12D/+, VillinCreER+ Apcfl/fl p53R172H/fl, VillinCreER+ Apcfl/fl p53R172H/fl KrasG12D/+). The 
cells were able to survive and recreate spheres that recapitulated the characteristics of the 
intestinal crypts. There was no difference in the growing pattern and characteristics 
between cells taken from already formed adenomas and cells taken from still non-tumoral, 
but already induced, crypts. Even more, cells transplanted into subcutaneous tissue of nude 
mice were able again to reproduce similar adenocarcinomas as seen in the intestine of the 
transgenic mice; in this case the cells had a very different environment to that of a culture 
plate but this did not change the tumorigenic capacities.  
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This clearly indicates the cells conserve the tumour phenotype and are able to form 
tumours  following culture and transplantation, which suggest all cells have tumour 
initiating capacities.  
This culture cell experiment would be valuable for studying the molecular characteristics 
of tumour growth and will allow elucidation of the role of intestinal stem cells in the 
tumorigenesis process.  
 
4.5 Role of other candidate genes in CRC 
There are quite a few genes that are also known to be implicated in the CRC disease and 
that needed to be further characterized. Two of these candidate genes are MYC and ARF.  
4.5.1 Myc deletions do not modify the VillinCreER+ Apcfl/+ p53fl/fl and 
VillinCreER+Apcfl/+ p53fl/fl KrasG12D/+ phenotypes 
Myc deletions in an Apc-deficient background have been observed to rescue the 
unrestricted intestinal crypt proliferative phenotype of the Apc loss, even the heterozygous 
condition (Mycfl/+) had an effect in partially reducing the proliferation of crypts (Athineos 
et al. 2010; Sansom et al. 2007). In our models, we observed overexpression of c-Myc at 
the invasive front of intestinal tumours. Given this, a deletion in Myc would theoretically 
reveal an effect in tumour progression and invasion. In the models we created 
(VillinCreER+ Apcfl/+ p53fl/fl and VillinCreER+Apcfl/+ p53fl/fl KrasG12D/+) the aditional single 
deletion of Myc (Mycfl/+) did not increase the survival rate of mice and did not reduce the 
tumour burden or total tumour number in either the VillinCreER+ Apcfl/+ p53fl/fl Mycfl/+ or 
VillinCreER+Apcfl/+ p53fl/fl KrasG12D/+ Mycfl/+ models. Moreover, there was no reduction in 
the percentage of invasive tumours in the intestine of these mice. While the previous 
studies were performed in an Apc Myc model, the addition of a p53 mutation in our models 
might have confered the cells the ability to compensate for the lack of Myc and which may 
explain why we did not observe a reduction in the formation of tumours as expected. 
Another possible explanation for these results is that, although in the experiment of 
Athineos et al, even a single deletion of Myc was able to rescue the Apc loss phenotype, 
our model contains additional double p53 deletion and Kras mutation, which may require a 
stronger effect from the lack of Myc, such as double deletion (Mycfl/fl) to be able to show 
the rescue phenotype observed in the experiment of Athineos. Further experiments are 
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therefore necessary in this field to characterize the effect of Myc deletion on an Apc p53 
Kras background.   
4.5.2 Arf deletion reduces the incidence of invasive tumours 
The ARF gene has been considered as a tumour suppressor gene for many years and its 
suppressor functions were actually demonstrated in a study of mouse embryogenic stem 
cells (Kamijo et al. 1997). In the past few years there has been an emerging theory that 
confers ARF tumour promoter characteristics (Humbey et al. 2008; Herkert et al. 2010). 
When Arf was deleted in our experiments, tumour survival rates were not increased in 
either the heterozygous or homozygous condition (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+
 
Arf 
fl/+ or VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/-) and there was no difference either in the 
tumour number or tumour burden across these cohorts. Regarding these results, we can 
state that, at least in our VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+
 
mouse model, deletion of Arf 
in the murine intestine, either single or double, did not confer any advantage for the tumour 
progression but neither for the prevention of tumour formation. In a study performed by 
Bennecke et al., lack of Ink4a/Arf in mice with a KrasG12D mutation allowed colorectal 
tumours to metastasize in the absence of Wnt pathway (Bennecke et al, 2010); although 
this study follows a different pathway than our models (absence of Wnt signalling), it 
would be interested to test in our model the possible effects of Arf deletion in the presence 
of Kras mutation alone (VillinCreER+ Apcfl/+ KrasG12D/+ Arf +/-). 
When the tumours were examined under the microscope, striking results were obtained. 
Mice carrying additional single or double deletions in Arf (VillinCreER+ Apcfl/+ p53fl/fl 
KrasG12D/+
 
Arf fl/+ or VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ Arf -/-) had significantly less 
numbers of invasive tumours than controls (VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+). These 
results strongly support the theory suggested by Herkert et al. who attributed to ARF the 
creation of the complex Myc/Miz1 that inhibits genes involved in cell to cell adhesion; in 
these experiments, the inhibition of the cell to cell adhesion lead to the apoptosis of the cell 
(Herkert et al. 2010). Following this theory, in the absence of apoptotic signals, such as 
loss of p53 as we have in our VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ mouse model, the 
inhibition of the cell to cell adhesion genes will not lead to immediate apoptosis but, 
instead, it would lead to the disgregation of epithelial cells and, therefore, the transition to 
a mesenchymal phenotype; in this context Arf will therefore act as a tumour promoter. Our 
results confirm that Arf, in a VillinCreER+ Apcfl/+ p53fl/fl KrasG12D/+ background, despite not 
having any apparent effect in the formation of tumours in the intestine, it actually has an 
effect in the progression of these tumours towards an invasive phenotype, probably 
71 
 
through its involvement in the cell-cell adhesion properties of the cells and the 
combination with p53 loss. Further studies will be important to understand the exact 
mechanisms involved in this process.  
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FUTURE WORK 
 
This model of colon cancer has been proven extremely useful for the study of later stages 
of cancer such as invasion through the intestinal wall thickness, progression to 
mesenchymal phenotype and metastasis to distant organs.  
We have, preliminarily, tested the drug Dasatinib, which has been effective in preventing 
the tumours from invading mainly via impeding the cells to exhibit EMT changes. Since 
Dasatinib inhibits other Kinases rather than only SRC (Araujo et al, 2010), the reduction in 
invasion observed in our experiment could have been related with the inhibition of oher 
kinases, not only SRC; the use of other more specific SRC inhibitors, such as Saracatinib, 
are therefore necessary to perform.  
 In addition, there are more factors involved in the process of invasion, such as the creation 
of a proper matrix to facilitate the infiltration of neoplastic cells into adjacent tissues.  In 
this context, lysyl oxidase (LOX) has a main role in catalyzing the cross linking of 
collagen and elastin in the extracellular matrix (ECM) and it has been directly implicated 
in promotion of the invasion and metastasis of some solid tumours, including colorectal 
cancer (Cox et al, 2011; Kirschmann et al, 2002; Baker et al, 2011). Recent studies have 
linked LOX with the reduced phosphorilation of SRC and there are evindence of abolition 
of LOX-associated dimensional growth of cells by treatment with Dasatinib (Baker et al, 
2011). Testing the LOX inhibitor, lox-ab, in our model would yield more information in 
this field and it may further characterizes the relation with Dasatinib.  
Another emerging factor involved in the invasion of cells is the ARF tumour suppressor 
gene.  Our results showed a possible role for this gene in the mesenchymal transition and 
therefore invasion of metastatic cells, this line of study could yield interesting results in the 
future.  
On the other hand, allograft injection of cultured cells from primary tumours in the mice 
has been seen to be successful in the first instance. Our aim is to develop other better 
models of metastasis using these cultured cells. The next step then is to inject the cells 
orthotopically into the intestinal mucosa of mice to assess the ability to invade the tissue 
and therefore metastasize. With these allografts and orthotopic models, we would then be 
able to test other drugs whose main effect is to repress the metastatic growth of the 
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neoplasms.  This will also provide a good framework in which further investigate the 
tumour initiating properties at the molecular level.  
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